Literature DB >> 28442271

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

Jason Grebely1, Francois M J Lamoury2, Behzad Hajarizadeh2, Yasmin Mowat2, Alison D Marshall2, Sahar Bajis2, Philippa Marks2, Janaki Amin3, Julie Smith4, Michael Edwards5, Carla Gorton6, Nadine Ezard7, David Persing8, Marika Kleman9, Philip Cunningham10, Beth Catlett10, Gregory J Dore2, Tanya L Applegate2.   

Abstract

BACKGROUND: Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage over antibody testing (which only indicates previous exposure), enabling diagnosis of active infection in a single visit. In this study, we evaluated the performance of the Xpert HCV Viral Load assay with venepuncture and finger-stick capillary whole-blood samples.
METHODS: Plasma and finger-stick capillary whole-blood samples were collected from participants in an observational cohort enrolled at five sites in Australia (three drug and alcohol clinics, one homelessness service, and one needle and syringe programme). We compared the sensitivity and specificity of the Xpert HCV Viral Load test for HCV RNA detection by venepuncture and finger-stick collection with the Abbott RealTime HCV Viral Load assay (gold standard).
FINDINGS: Of 210 participants enrolled between Feb 8, 2016, and July 27, 2016, 150 participants had viral load testing results for the three assays tested. HCV RNA was detected in 45 (30% [95% CI 23-38]) of 150 participants based on Abbott RealTime. Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in plasma collected by venepuncture was 100·0% (95% CI 92·0-100·0) and specificity was 99·1% (95% CI 94·9-100·0). Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in samples collected by finger-stick was 95·5% (95% CI 84·5-99·4) and specificity was 98·1% (95% CI 93·4-99·8). No adverse events caused by the index test or the reference standard were observed. IMPLICATIONS: The Xpert HCV Viral Load test can detect active infection from a finger-stick sample, which represents an advance over antibody-based tests that only indicate past or previous exposure. FUNDING: National Health and Medical Research Council (Australia), Cepheid, South Eastern Sydney Local Health District (Australia), and Merck Sharp & Dohme (Australia).
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28442271     DOI: 10.1016/S2468-1253(17)30075-4

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  28 in total

1.  Hepatitis: A step closer to easy point-of-care testing for HCV?

Authors:  Katrina Ray
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-10       Impact factor: 46.802

2.  Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.

Authors:  Heather Valerio; Maryam Alavi; David Silk; Carla Treloar; Marianne Martinello; Andrew Milat; Adrian Dunlop; Jo Holden; Charles Henderson; Janaki Amin; Phillip Read; Philippa Marks; Louisa Degenhardt; Jeremy Hayllar; David Reid; Carla Gorton; Thao Lam; Gregory J Dore; Jason Grebely
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

Review 3.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

Review 4.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

5.  6th Canadian Symposium on Hepatitis C Virus: Delivering a cure for hepatitis C infection-What are the remaining gaps?

Authors:  Sarwat Khan; Annie Bernier; Dustin Dapp; Emmanuel Fortier; Mel Krajden; Alexandra King; Jason Grebely; Selena M Sagan; Curtis L Cooper; Angela M Crawley
Journal:  Can Liver J       Date:  2018-07-17

6.  A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.

Authors:  Sunil S Solomon; Sandra Wagner-Cardoso; Laura Smeaton; Leonard A Sowah; Chanelle Wimbish; Gregory Robbins; Irena Brates; Christine Scello; Annie Son; Anchalee Avihingsanon; Benjamin Linas; Donald Anthony; Estevão Portela Nunes; Dimas A Kliemann; Khuanchai Supparatpinyo; Cissy Kityo; Pablo Tebas; Jaclyn Ann Bennet; Jorge Santana-Bagur; Constance A Benson; Marije Van Schalkwyk; Nelson Cheinquer; Susanna Naggie; David Wyles; Mark Sulkowski
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-01-10

7.  Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.

Authors:  Aung H Bwa; Gayatri Nangia; Si T S Win; Soe T Maung; Khin A W Han; Su S Htar; Lei Y Wine; Wint W Ko; Moe P Oo; Naomi K T Hlaing; Julia Palecki; Bao L Loza; Khin M Win; Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2018-12-19

Review 8.  The Elimination of Hepatitis C as a Public Health Threat.

Authors:  Margaret Hellard; Sophia E Schroeder; Alisa Pedrana; Joseph Doyle; Campbell Aitken
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

9.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Authors:  Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2017-07-03

10.  Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.

Authors:  J Morgan Freiman; Jianing Wang; Philippa J Easterbrook; C Robert Horsburgh; Francesco Marinucci; Laura F White; George Kamkamidze; Mel Krajden; Anne Loarec; Richard Njouom; Kihn V Nguyen; Gamal Shiha; Reham Soliman; Sunil S Solomon; Tengiz Tsertsvadze; Claudia M Denkinger; Benjamin Linas
Journal:  J Hepatol       Date:  2019-02-21       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.